Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: A purified and isolated peptide comprises an amino acid sequence of SEQ ID NOs: 1 to 8. A method is also provided for preventing interaction, e.g. binding, of EN1 with EPRS in a cell by introducing, into the cell, a peptide having a sequence of SEQ ID NOs: 1 to 8, which results in the peptide interacting with EPRS thereby preventing an interaction of EPRS with EN1. Apoptosis can be induced in a cell expressing either or both of EN1 and EN2, by introducing into the cell, a peptide of SEQ ID NOs: 1 to 8.

Abstract: Provided herein are biomolecule conjugates, and methods of use thereof, wherein the conjugate comprises a cytokine, typically an immunopotentiating cytokine, and a peptide comprising or consisting of the sequence CSGRRSSKC (SEQ ID NO:1). Biomolecule conjugates of the invention find application, inter alia, in the treatment of turnouts, atherosclerosis and fibrosis, and the degradation of ECM associated therewith. Also provided herein are uses of a peptide comprising or consisting of the sequence of SEQ ID NO:1, optionally linked to a delectable agent and/or a carrier, in the detection and/or localisation of tumour, atherosclerotic and fibrotic tissue.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: The invention relates to a medical device for obtaining a material sample from a material. The medical device comprises a first member comprising a receptacle for receiving the material sample; and a second member having a hollow region for accommodating at least a portion of the first member such that the at least a portion of the first member is movable within the second member. The first and second members are arranged such that when the material sample is received in the receptacle of the first member, the material sample can be obtained by moving the first member within the second member. The medical device further comprises an optical element arranged to receive electromagnetic radiation that can be used to determine information in relation to the material. The medical device has a distal end for inserting the medical device into the material.

Abstract: The present disclosure relates to a method of fabricating a reflector, the reflector being at least partially reflective and at least partially transmissive for at least a wavelength of electromagnetic radiation; the method comprising: forming a first material layer defining a bottom layer; forming a sacrificial layer on the bottom layer; forming a second material layer defining a top layer on the sacrificial layer and a supporting structure connected to the bottom layer; and removing at least part of the sacrificial layer to form a cavity between the bottom layer and the top layer such that the supporting structure supports the top layer relative to the bottom layer and no further supporting structure is provided within the cavity, wherein after the at least part of the sacrificial layer is removed, at least the top layer has residual tensile stress.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: Provided are cytochrome P450 polypeptides, including cytochrome P450 santalene oxidase polypeptides, cytochrome P450 bergamotene oxidase polypeptides and cytochrome P450 reductase polypeptides. Also provided are nucleic acid molecules encoding the cytochrome P450 polypeptides. Cells containing the nucleic acids and/or the polypeptides are provided as are methods for producing terpenes, such as santalols and bergamotols, by culturing the cells.

Abstract: The present invention relates generally to methods and compositions for the treatment of cancers expressing the type 1 insulin-like growth factor receptor (IGF1R) or a constituent of an IGF1R signaling pathway, in particular melanoma, using the microRNA miR-7-5p. Also provided are methods for increasing the sensitivity of such cancers to therapeutic agents.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Abstract: Biomarkers for abnormal kidney function, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV, and methods for their use in assessing abnormal kidney function are disclosed herein.

Abstract: The invention relates to a medical device for obtaining a material sample from a material. The medical device comprises a first member comprising a receptacle for receiving the material sample; and a second member having a hollow region for accommodating at least a portion of the first member such that the at least a portion of the first member is movable within the second member. The first and second members are arranged such that when the material sample is received in the receptacle of the first member, the material sample can be obtained by moving the first member within the second member. The medical device further comprises an optical element arranged to receive electromagnetic radiation that can be used to determine information in relation to the material. The medical device has a distal end for inserting the medical device into the material.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: A recombinant polypeptide is described including at least one PUF RNA-binding domain capable of specifically binding to a cytosine RNA base. The PUF RNA-binding domain of the polypeptide includes at least one RNA base-binding motif of the general formula X1X2X3X4X5X6X7X8X9X10X11 wherein X1 is selected from a defined group and wherein the RNA base-binding motif is operably capable of specifically binding to a cytosine RNA base.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

Abstract: The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

Abstract: There is provided an apparatus 2 for desalinating non-potable water. The apparatus has a first vapor producing module 5 configured to receive a heated working fluid for producing vapor from a volume of non-potable water for driving at least one first distillation module 10 for producing condensate 12. The apparatus also includes a second vapor producing module 14 configured to receive working fluid from the first vapor producing module 5 for producing additional vapor from a further volume of non-potable water 8?.

Abstract: The present invention relates to methods for generating mature insulin-producing ?-like cells comprising the steps: (a) isolating, purifying and/or enriching ?-cell progenitor cells from a population of cells; (b) differentiation of the ?-cell progenitor cells into immature insulin-producing ?-like cells; and (c) maturation of the immature insulin-producing ?-like cells into mature insulin-producing ?-like cells, comprising exposing the immature insulin-producing ?-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing ?-like cells for use in treating diabetes.